LW106

LW106 is a selective IDO1 inhibitor with an IC50 of 1.57 μM. LW106 has no inhibitory effect on IDO2 and TDO. LW106 inhibits tumor outgrowth by limiting stroma-immune crosstalk and CSC enrichment in the tumor microenvironment. LW106 reduces subpopulation of cancer stem cells (CSCs) in xenografted tumors in which less proliferative/invasive tumor cells and more tumor cells apoptosis. LW106 can be used for the studies of lung cancer and melanoma[1].

Product Specifications

CAS Number

[2116519-76-5]

UNSPSC

12352005

Target

Apoptosis; Indoleamine 2,3-Dioxygenase (IDO) ; SWI/SNF Complex

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

O/N=C(N1CC2=C(C1)C=CC=C2)/C3=NON=C3N

Molecular Formula

C11H11N5O2

Molecular Weight

245.24

References & Citations

[1]Fu R, et al. LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment. Br J Pharmacol. 2018 Jul;175 (14) :3034-3049.